You are using an older browser version. Please use a supported version for the best MSN experience.

VASCULAR BIOGENICS LTD

NASDAQ: VBLT
1.22
-0.01
-0.76%

Sector

Healthcare

Industry

Biotechnology & Medical Research

Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.

Key People

Bennett M. Shapiro

Chairman of the Board, Independent Director

Dror Harats

Chief Executive Officer, Director

Amos Ron

Chief Financial Officer & Company Secretary

Eyal Breitbart

Vice President - Research & Operations

Erez Feige

Vice President - Business Operations

  • Vascular Biogenics Ltd

  • 8 HaSatat St.

  • MODIIN, 7178106

  • IL.Map

  • Phone: +972 8 9935000

  • Fax: +972 8 9935001

  • vblrx.com

Incorporated

2000

Employees

38

Insider Trades
  • Recent
  • All
Data not available
Data not available
AdChoices
AdChoices
AdChoices
image beaconimage beaconimage beacon